Wall Street Estimates That CRISPR Therapeutics Stock Could Jump 49%. Here's Why That's Right.The Motley Fool • 06/27/23
Cathie Wood Is Buying This Growth Stock and Selling Its Competitor. Should You Follow Suit?The Motley Fool • 06/21/23
Buying This Growth Stock Hand-Over-Fist Right Now Could Make You a Lot Wealthier by 2030The Motley Fool • 06/21/23
CRISPR Therapeutics to Participate in Goldman Sachs 44th Annual Global Healthcare ConferenceGlobeNewsWire • 06/13/23
This Move Is a First for the FDA. Could It Signal a Big Turning Point for CRISPR Therapeutics?The Motley Fool • 06/13/23